Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Prime Medicine, Inc. Banner

Prime Medicine, Inc.

PRME Stock Analysis

Page title

Section title

About Prime Medicine, Inc.

Biotechnology
Healthcare

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc. Key Metrics

Market Cap
$495M
52 Weeks Low
$3.47
52 Weeks High
$11.51
P/B
2.50x
P/E
-2.26x
P/S
836.76x

Upcoming Events

    PRME Analyst Forecasts

    ‌
    ‌

    PRME Financials

    PRME Income Statement Key Metrics

    • Revenue(TTM)591,000
    • Gross Profit(TTM)0
    • EBITDA(TTM)-189.48 M
    • Net Income(TTM)-217.44 M
    • EPS Diluted(TTM)-2.12

    Decode PRME's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    PRME earnings and revenue history

    PRME Return on Equity

    See how efficiently PRME generates profit for it's shareholders.

    -148.89%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of PRME (-1.489) is lower than the average of its peers (-0.702).

    Return on Equity Growth

    PRME's Return on Equity has shown poor growth over the past 10 years, increasing by only -3.94%.

    PRME Revenue Growth

    See how PRME has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    PRME's revenue has shown poor growth over the past 10 years, increasing by only 0%.